Introduction Hepatocellular carcinoma (HCC) is the sixth most common cancer and the fourth leading cause of cancer-related death in the world ( Systemic treatments with sorafenib or lenvatinib followed by regorafenib, nivolumab, or ramucirumab have been demonstrated to improve survival ( Hepatocyte growth factor (HGF) and its high-affinity receptor, mesenchymal epithelial transition factor (c-Met), are closely related to the onset, progression and metastasis of multiple tumors
*Correspondence: Ricard Farre [email protected] This article was submitted to Nutritional Immunology, a section of the journal Frontiers in Nutrition Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Oncogene 12 (12), 25552562
2 MONTHS +12 LBS I plateaued on Tirzepatide at 15 mg and flipped to the 2 mg of Retatrutide and Ive already lost 12 additional pounds and have A TON of Energy
Ren, K., He, C., Xiao, C., Li, G